.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Fuji
Cipla
US Army
McKinsey
UBS
Julphar
QuintilesIMS
McKesson
Deloitte

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,150,380

« Back to Dashboard

Which drugs does patent 6,150,380 protect, and when does it expire?


Patent 6,150,380 protects PRILOSEC and is included in one NDA.

Protection for PRILOSEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,150,380

Title: Crystalline form of omeprazole
Abstract:The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole.
Inventor(s): Lovqvist; Karin (Molndal, SE), Sunden; Gunnel (Goteborg, SE), Noreland; David (Sodertalje, SE), Ymen; Ingvar (Saltsjo-Boo, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:09/202,251
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca PharmsPRILOSEComeprazoleCAPSULE, DELAYED REL PELLETS;ORAL019810-003Oct 5, 1995DISCNYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsPRILOSEComeprazoleCAPSULE, DELAYED REL PELLETS;ORAL019810-001Sep 14, 1989DISCNYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsPRILOSEComeprazoleCAPSULE, DELAYED REL PELLETS;ORAL019810-002Jan 15, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,150,380

PCT Information
PCT FiledNovember 10, 1998PCT Application Number:PCT/SE98/02028
PCT Publication Date:February 25, 1999PCT Publication Number: WO99/08500

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Merck
Queensland Health
Daiichi Sankyo
Mallinckrodt
Citi
US Army
Deloitte
Boehringer Ingelheim
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot